The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
NCT06601010 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2024-12-11
Summary
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.
Conditions
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-24
- Primary Completion
- 2026-07-31
- Completion
- 2027-08-31
Countries
- China
Study Locations
More Related Trials
-
Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer
NCT06203613 ·Status: RECRUITING ·Phase: NA
-
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
NCT07172503 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
68Ga-ICAM-1pep PET/CT in Cancer Patients
NCT04596670 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
NCT06684028 ·Status: RECRUITING ·Phase: NA
-
Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer
NCT00885248 ·Status: UNKNOWN
-
Target-specific immunoPET Imaging of Digestive System Carcinoma
NCT06715839 ·Status: RECRUITING ·Phase: NA
-
Clinical Study of TROP-2 PET/CT for Noninvasive Diagnosis of Solid Tumors
NCT06203574 ·Status: RECRUITING ·Phase: NA
-
CD70-targeted immunoPET Imaging of Kidney Cancer
NCT06680089 ·Status: RECRUITING ·Phase: PHASE2
-
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
NCT04831541 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma
NCT06148155 ·Status: RECRUITING ·Phase: NA
-
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
NCT04525612 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Trop2-targeted immunoPET Imaging of Solid Tumors
NCT06851663 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
NCT04588064 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer
NCT02550847 ·Status: UNKNOWN
-
68Ga-FAPI PET/CT in Patients With Various Types of Cancer
NCT04499365 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression
NCT06289517 ·Status: RECRUITING ·Phase: NA
-
Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients
NCT02245217 ·Status: COMPLETED ·Phase: NA
-
Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
NCT05930457 ·Status: COMPLETED ·Phase: PHASE1
-
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
NCT03636607 ·Status: WITHDRAWN ·Phase: NA
-
68Ga-DOTA-hLAG-3 PET Imaging of LAG-3 Expression in Cancers
NCT05346276 ·Status: COMPLETED
-
Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Based on Incoherent Undersampling
NCT02944006 ·Status: UNKNOWN
-
Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging
NCT06715020 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
68Ga-NI-FAPI PET/CT: First-in-human Study
NCT06688305 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours
NCT06770478 ·Status: RECRUITING ·Phase: NA